May 20, 2023 06:00 AM EDT

FTC’s M&A crackdown; NASH drug gets thumbs down; FDA OKs topical gene therapy; Company exits frustrate rare disease families; and more

Amber Tong

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FTC’s M&A crackdown; NASH drug gets thumbs down; FDA OKs topical gene therapy; Company exits frustrate rare disease families; and more

Amber Tong

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Boehringer’s updated results in HER2-mutated lung cancer impress

Novavax responds to FDA’s trial ask, with Covid vaccine strain updates under scrutiny

GSK’s checkpoint blocker Jemperli cures biomarker-driven rectal cancer

Merck KGaA to buy rare cancer biotech SpringWorks for $3.9B

Scholar Rock names new CEO, adds biotech veterans in C-suite rebuild

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

FTC’s M&A crack­down; NASH drug gets thumbs down; FDA OKs top­i­cal gene ther­a­py; Com­pa­ny ex­its frus­trate rare dis­ease fam­i­lies; and more

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

FTC’s M&A crackdown; NASH drug gets thumbs down; FDA OKs topical gene therapy; Company exits frustrate rare disease families; and more